To develop and conduct clinical trials aimed at improving the treatment and prevention of cancer with the ultimate goal of reducing morbidity and mortality from this disease.

About Us

The Canadian Cancer Trials Group is a cooperative oncology group which carries out clinical trials in cancer therapy, supportive care and prevention across Canada and internationally. It is one of the national programmes and networks of the Canadian Cancer Society Research Institute (CCSRI), and is supported by the Canadian Cancer Society (CCS).

Faculty Researchers

Meet the Faculty Researchers


The information contained in this website is intended for use by Canadian Cancer Trials Group members at participating centres.

Recently Activated

  • BRC6 
    A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer
  • CO26 
    A Phase II Randomized Study of Durvalumab and Tremelimumab and Best Supportive Care vs Best Supportive Care Alone in Patients with Advanced Colorectal Adenocarcinoma Refractory to Standard Therapies
  • I225 
    A Phase II Study of the Assessment of Response to Pembrolizumab in Metastatic Melanoma: CT Texture Analysis as a Predictive Biomarker
  • I227 
    A Phase II Randomized Study of Pembrolizumab in Patients with Advanced Malignant Pleural Mesothelioma
  • I228 
    A Phase II Study of Durvalumab and Tremelimumab in Patients with Advanced Rare Tumours
  • I229 
    A Phase 1b PD Study of Durvalumab in Patients with HER-2+ Metastatic Breast Cancer Receiving Trastuzumab
  • I231 
    A Phase I/II Study of CX5461
  • I232 
    A Phase II Study of Durvalumab (MEDI4736) With or Without Tremelimumab in Patients With Metastatic Castration Resistant Prostate Cancer
  • ME13 
    Randomized Phase III Trial of the Duration of Anti-PD-1 Therapy in Metastatic Melanoma (STOP-GAP)
  • PA7 
    A Randomized Phase II Trial of Gemcitabine and Nab-Paclitaxel vs Gemcitabine, Nab-Paclitaxel, Durvalumab and Tremelimumab as 1st Line Therapy in Metastatic Pancreatic Adenocarcinoma
  • REC3 
    A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors Cabozantinib, Crizotinib, Savolitinib, and Sunitinib in Metastatic Papillary Renal Carcinoma (PAPMET)
  • Planned Trials

  • ALC4 
    A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults.
  • CEC5 
    Corticosteroid with either Bevacizumab or Placebo for Radionecrosis after Surgery for Brain Metastases
  • CO27 
    Irinotecan and Oxaliplatin for Colon cancer in the Adjuvant Setting: mFOLFIRINOX triplet chemotherapy for high-risk stage III colon cancer in adjuvant setting (IROCAS study): A Phase III Randomised Trial
  • GA3 
    A Randomised Phase III Double-Blind Placebo-Controlled Study of Regorafenib in Refractory Advanced Gastro-Oesophageal Cancer (AGOC)
  • I223 
    A Phase II Study of Palbociclib, A CDK4/6 Inhibitor, in Patients with Metastatic Castration-Resistant Prostate Cancer
  • I230 
    A Phase II Trial of Durvalumab and Tremelimumab in Pretreated, Metastatic or Locally Refractory Estrogen Receptor Positive, HER2 negative Breast Cancer
  • MA37 
    A Randomized Phase III Trial of Palbociclib with Adjuvant Endocrine Therapy versus Adjuvant Endocrine Therapy alone for HR+/HER2 Negative Early Breast Cancer
  • MAC20 
    Randomized Phase III Trial Evaluating the Role of Weight Loss In Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
  • OVC1 
    A Phase III Single-agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-based Chemotherapy in Women with Recurrent Platinum-sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
  • OVC2 
    Phase II/III combination of Cediranib and Olaparib compared to Cediranib or Olaparib alone, or Standard of care chemotherapy in women with recurrent platinum-resistant or -refractory ovarian, fallopian tube, or primary peritoneal cancer (COCOS)
  • PR18 
    TOPARP: Phase II Trial of Olaparib in Patients with Advanced Castration Resistant Prostate Cancer
  • PR19 
    A Randomized Phase II Trial Evaluating High Dose Rate Brachytherapy and Low Dose Rate Brachytherapy as Monotherapy in Localized Prostate Cancer